Switching from natalizumab to anti-CD20 monoclonal antibodies: optimal timing and safety analysis

被引：0
|
作者：
Levin, S. [1 ]
Levine, L. [1 ]
Vargas, W. [1 ]
Straus-Farber, R. [1 ]
De Jager, P. [1 ]
Riley, C. [1 ]
机构：
[1] Columbia Univ, Dept Neurol, Med Ctr, New York, NY USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2019年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P670
引用
收藏
页码：333 / 333
页数：1
相关论文
共 50 条
  • [1] Switching from natalizumab to an anti-CD20 monoclonal antibody in relapsing remitting multiple sclerosis: A systematic review
    Brown, Justin D.
    Muston, Benjamin T.
    Massey, Jennifer
    [J]. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2024, 86
  • [2] Anti-CD20 monoclonal antibodies: reviewing a revolution
    Casan, J. M. L.
    Wong, J.
    Northcott, M. J.
    Opat, S.
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2018, 14 (12) : 2820 - 2841
  • [3] Anti-CD20 monoclonal antibodies in multiple sclerosis
    Moreno Torres, Irene
    Garcia-Merino, Antonio
    [J]. EXPERT REVIEW OF NEUROTHERAPEUTICS, 2017, 17 (04) : 359 - 371
  • [4] Mechanisms of killing by anti-CD20 monoclonal antibodies
    Glennie, Martin J.
    French, Ruth R.
    Cragg, Mark S.
    Taylor, Ronald P.
    [J]. MOLECULAR IMMUNOLOGY, 2007, 44 (16) : 3823 - 3837
  • [5] Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies
    Taylor, Ronald P.
    Lindorfer, Margaret A.
    [J]. CURRENT OPINION IN IMMUNOLOGY, 2008, 20 (04) : 444 - 449
  • [6] Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia
    Jain, Preetesh
    O'Brien, Susan
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2013, 13 (02) : 169 - 182
  • [7] Anti-CD20 monoclonal antibodies: historical and future perspectives
    Lim, Sean H.
    Beers, Stephen A.
    French, Ruth R.
    Johnson, Peter W. M.
    Glennie, Martin J.
    Cragg, Mark S.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (01): : 135 - 143
  • [8] Chronic Lymphocytic Leukemia and anti-CD20 monoclonal antibodies
    Reslan, Lina
    Dalle, Stephane
    Mestas, Jean-Louis
    Tournebize, Cindy
    Dumontet, Charles
    [J]. BULLETIN DU CANCER, 2010, 97 : S60 - S60
  • [9] New anti-CD20 monoclonal antibodies: which is the best?
    Gagez, Anne-Laure
    Cartron, Guillaume
    [J]. LEUKEMIA & LYMPHOMA, 2015, 56 (01) : 1 - 2
  • [10] Characteristics of Patients Switching from Anti-CD20 Therapy to Natalizumab in the Treatment of Multiple Sclerosis
    Vollmer, Brandi
    Nair, Kavita
    Corboy, John
    Vollmer, Timothy
    Alvarez, Enrique
    [J]. NEUROLOGY, 2019, 92 (15)
12345